Segment and Geographic Area Information (Details) $ in Millions	3 Months Ended								12 Months Ended
	Dec. 31, 2015 USD ($)	Sep. 30, 2015 USD ($)	Jun. 30, 2015 USD ($)	Mar. 31, 2015 USD ($)	Dec. 31, 2014 USD ($)	Sep. 30, 2014 USD ($)	Jun. 30, 2014 USD ($)	Mar. 31, 2014 USD ($)	Dec. 31, 2015 USD ($) segment customer	Dec. 31, 2014 USD ($)	Dec. 31, 2013 USD ($)
Segment and Geographic Area Information
Number of Operating Segments | segment									1
Number of principal customers | customer									3
Segment Information
Net revenues	$ 6,400	$ 5,944	$ 5,475	$ 5,040	$ 5,452	$ 5,019	$ 4,926	$ 4,563	$ 22,859	$ 19,960	$ 18,790
Revenue, Net	$ 6,400	$ 5,944	$ 5,475	$ 5,040	$ 5,452	$ 5,019	$ 4,926	$ 4,563	22,859	19,960	18,790
H U M I R A
Segment Information
Net revenues									14,012	12,543	10,659
Revenue, Net									14,012	12,543	10,659
IMBRUVICA
Segment Information
Net revenues									754
Revenue, Net									754
VIEKIRA
Segment Information
Net revenues									1,639	48
Revenue, Net									1,639	48
Creon
Segment Information
Net revenues									632	516	412
Revenue, Net									632	516	412
Synagis
Segment Information
Net revenues									740	835	827
Revenue, Net									740	835	827
Lupron
Segment Information
Net revenues									826	778	785
Revenue, Net									826	778	785
Synthroid
Segment Information
Net revenues									755	709	622
Revenue, Net									755	709	622
Kaletra
Segment Information
Net revenues									700	870	962
Revenue, Net									700	870	962
Andro Gel
Segment Information
Net revenues									694	934	1,035
Revenue, Net									694	934	1,035
Sevoflurane
Segment Information
Net revenues									474	550	568
Revenue, Net									474	550	568
Duodopa
Segment Information
Net revenues									231	220	178
Revenue, Net									231	220	178
Dyslipidemia Products
Segment Information
Net revenues									179	328	1,076
Revenue, Net									179	328	1,076
Other Products
Segment Information
Net revenues									1,223	1,629	1,666
Revenue, Net									$ 1,223	$ 1,629	$ 1,666